Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.

Gastroenterology - 1 Jan 2004

Perrillo Robert, Hann Hie-Won, Mutimer David, Willems Bernard, Leung Nancy, Lee William M, Moorat Alison, Gardner Stephen, Woessner Mary, Bourne Eric, Brosgart Carol L, Schiff Eugene

Abstract excerpt

BACKGROUND AND AIMS: Prolonged lamivudine therapy is associated with treatment-resistant YMDD mutant hepatitis B virus (HBV). We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV. METHODS: Ninety-five pa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine Transaminase
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 14699490
DOI: 10.1053/j.gastro.2003.10.050

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-14699490-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.PMID 14699490Read ↗

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment.Semantic proximity Read ↗

Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.Semantic proximity Read ↗

Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.Semantic proximity Read ↗

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.Semantic proximity Read ↗

Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.Semantic proximity Read ↗

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.Semantic proximity Read ↗

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.